Chromocell Therapeutics Corp (CHRO)

$0.57 -0.06 (-8.83%)
Market Cap 3.80M
Revenue (ttm) 0.00
Net Income (ttm) -7.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.60
Volume 45,954
Avg Vol 164,590
Day's Range N/A - N/A
Shares Out 6.03M
Stochastic %K 38%
Beta N/A
Analysts Strong Buy
Price Target $8.50

Company Profile

Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 265 8266
Address:
4400 Route 9 South, Suite 1000, Freehold, United States
Latest News on CHRO
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

Jun 27, 2025, 9:15 AM EDT - 4 weeks ago

Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

May 1, 2025, 5:00 PM EDT - 3 months ago

Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

Dec 20, 2024, 9:00 AM EST - 7 months ago

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

Dec 18, 2024, 8:30 AM EST - 7 months ago

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

Nov 21, 2024, 9:49 AM EST - 8 months ago

Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

Oct 29, 2024, 8:30 AM EDT - 9 months ago

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

Chromocell Announces Amendment to Stock Repurchase Plan

Oct 24, 2024, 8:45 AM EDT - 9 months ago

Chromocell Announces Amendment to Stock Repurchase Plan

Chromocell to Participate in Life Sciences Investor Forum September 19th

Sep 16, 2024, 8:35 AM EDT - 11 months ago

Chromocell to Participate in Life Sciences Investor Forum September 19th

Chromocell Announces Stock Repurchase Plan

Aug 7, 2024, 8:45 AM EDT - 1 year ago

Chromocell Announces Stock Repurchase Plan

Chromocell to Participate in the Virtual Investor Lunch Break Series

Jul 15, 2024, 9:00 AM EDT - 1 year ago

Chromocell to Participate in the Virtual Investor Lunch Break Series

Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024

May 13, 2024, 9:00 AM EDT - 1 year ago

Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Mar 21, 2024, 8:30 AM EDT - 1 year ago

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

Mar 18, 2024, 10:00 AM EDT - 1 year ago

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

Mar 11, 2024, 9:00 AM EDT - 1 year ago

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

Feb 27, 2024, 8:00 AM EST - 1 year ago

Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

Feb 21, 2024, 4:47 PM EST - 1 year ago

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week

Feb 17, 2024, 7:45 AM EST - 1 year ago

U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week

AMDI MTRS RCAT SSII UMAC WETH

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

Feb 16, 2024, 8:00 AM EST - 1 year ago

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

IPO Update: Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO

Oct 19, 2023, 5:31 PM EDT - 1 year ago

IPO Update: Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO

Chromocell Therapeutics Seeks IPO For Erythromelalgia Treatment

Feb 2, 2023, 1:35 PM EST - 2 years ago

Chromocell Therapeutics Seeks IPO For Erythromelalgia Treatment